Lachey Jennifer
SEC CIK 1808322 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | CSO | 141.1K | — | $4.98M | 26 | 2021-08-17 | 2022-07-15 |
Most active insiders at KROS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneeberger Daniel | 10% | — | $95.66M |
| 2 | Pontifax (China) IV L.P. | 10% | — | $84.98M |
| 3 | Cho Esther | SVP, GC | — | $123.7K |
| 4 | Seehra Jasbir | CEO, Dir | — | $113.4K |
| 5 | Lerner Lorena Raquel | CSO | — | $100.0K |
| 6 | Regnante Keith | CFO | — | $77.5K |
| 7 | BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| 8 | Knowles Julius | Dir | — | $28.2K |
| 9 | Farzan Nima | Dir | — | $28.2K |
| 10 | Seth Alpna | Dir | — | $28.1K |
Lachey Jennifer made no open-market trades at KROS in the last 12 months.
Transactions 26
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-19 | 2022-07-15 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +46.0K | 141.1K | +48% | +$13.8K |
| D | 2022-07-19 | 2022-07-15 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $30.00 | -46.0K | 95.1K | -33% | -$1.38M |
| D | 2022-07-15 | 2022-07-13 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +1,916 | 93.2K | +2% | +$574.80 |
| D | 2022-07-15 | 2022-07-13 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $30.00 | -1,916 | 95.1K | -2% | -$57.5K |
| D | 2022-06-14 | 2022-06-14 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +9,400 | 95.1K | +11% | +$2,820 |
| D | 2022-05-13 | 2022-05-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +5,300 | 91.0K | +6% | +$1,590 |
| DM | 2022-05-13 | 2022-05-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $41.90 | -5,300 | 85.7K | -6% | -$222.0K |
| DM | 2022-04-13 | 2022-04-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $62.77 | -5,300 | 86.3K | -6% | -$332.7K |
| D | 2022-04-13 | 2022-04-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +5,300 | 91.0K | +6% | +$1,590 |
| D | 2022-04-06 | 2022-04-04 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +7,950 | 93.7K | +9% | +$2,385 |
| D | 2022-04-06 | 2022-04-04 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $60.00 | -7,950 | 85.7K | -8% | -$477.0K |
| DM | 2022-03-15 | 2022-03-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $53.38 | -2,650 | 85.7K | -3% | -$141.4K |
| D | 2022-03-15 | 2022-03-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| DM | 2022-02-15 | 2022-02-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $52.06 | -2,650 | 85.9K | -3% | -$138.0K |
| D | 2022-02-15 | 2022-02-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| D | 2022-01-13 | 2022-01-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| DM | 2022-01-13 | 2022-01-11 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $53.75 | -2,650 | 88.0K | -3% | -$142.4K |
| D | 2022-01-07 | 2022-01-05 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 88.3K | +3% | +$795 |
| D | 2022-01-07 | 2022-01-05 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $60.00 | -2,650 | 85.7K | -3% | -$159.0K |
| DM | 2021-12-15 | 2021-12-13+ | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $50.40 | -2,650 | 85.7K | -3% | -$133.6K |
| DM | 2021-12-15 | 2021-12-13+ | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +2,650 | 87.6K | +3% | +$795 |
| DM | 2021-11-12 | 2021-11-10+ | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $59.91 | -21.2K | 90.3K | -19% | -$1.27M |
| DM | 2021-11-12 | 2021-11-10+ | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +21.2K | 101.6K | +26% | +$6,360 |
| D | 2021-11-05 | 2021-11-04 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +10.6K | 96.3K | +12% | +$3,180 |
| D | 2021-11-05 | 2021-11-04 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | S - Sale+OE | $50.00 | -10.6K | 85.7K | -11% | -$530.0K |
| D | 2021-08-18 | 2021-08-17 | KROS | Keros Therapeutics, Inc. | Lachey Jennifer | CSO | M - OptEx | $0.3 | +1,293 | 85.7K | +2% | +$387.90 |
Purchase Sale Sale after option exercise All abbreviations